ALFA Finder| Revenue growth | 16.6% YoY in Q4; 12.2% for FY26. |
|---|---|
| Margins | Normalized FY26 EBITDA margin stable at 28.3%. |
| Demand visibility | High; driven by aging population and chronic disease prevalence. |
| Management confidence | Strong; emphasizing resilience of business model and digital scale-up. |
Growth
Q4 revenue grew 16.6%; FY26 revenue up 12.2% to ₹2,763 cr. FY26 PAT rose 3.6% to ₹510 cr.
Outlook
Focus on AI-powered 'Sovaaka' wellness brand, digital transformation, and expanding infrastructure in South and West India.
Risks
Impact of new labour code (₹30 cr) and intense market fragmentation from standalone and hospital labs.
Earnings Call filed with NSE, NSE: LALPATHLAB. Summary written with AI assistance from the document.
Dr. Lal Pathlabs Ltd: key numbers
- Share price
- ₹2,039.70
- Market cap
- ₹34,236 Cr
- Revenue (annual)
- ₹2,763 Cr
- Net profit (annual)
- ₹504.8 Cr
- P/E (TTM)
- 58.7×Sector 54.5×
- Promoter holding
- 52.93%-0.26% QoQ
- FII holding
- 18.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Lal Pathlabs Ltd
All →Dr. Lal Pathlabs Management Change
Dr. Lal Path Labs appointed Ms. Vasuta Agarwal as an additional Non-Executive Independent Director for three years from 4 November 2026. Her appointment is subject to member approval by postal ballot.
- Execution
- 36 months from 04-11-2026
Dr. Lal Pathlabs Capital Structure Change
Dr. Lal PathLabs will invest up to Rs 49.5 Crore in its wholly owned Dubai subsidiary, in tranches. Funds cover operations and further investment in Ghana's SHL.
- Value
- ₹49.50 Cr
- Execution
- Indicative completion by 31 March 2027, in tranches
Dr. Lal Pathlabs Dividend
Dr. Lal Path Labs approved a Rs 5 per share second interim dividend. Record date is November 11, 2026; payment by December 3, 2026.
Dr. Lal Pathlabs Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs 874 Cr (+19.6%), EBITDA Rs 280 Cr (32.1% margin), PAT Rs 194 Cr (+27.5%). Strategy: AI diagnostics, rural GraminFit, M&A.
Dr. Lal Pathlabs Q2 FY27 Results: Net Profit ₹193.9 Cr, Up 27.4% YoY
Dr. Lal Pathlabs Ltd reported revenue from operations of ₹873.9 Cr (+19.6% YoY) and net profit of ₹193.9 Cr (+27.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹193.9 Cr · +27.4% YoY
Dr. Lal Pathlabs Board Meeting Date
Dr. Lal PathLabs updated its 4 November 2026 board meeting notice to add a possible second interim dividend. The meeting will also approve unaudited quarterly results.